Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the awarding of the contract for clinical research organization (“CRO”) services to California-based InClin, Inc. This move is in line with the company’s upcoming Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study, HYPER-H23-1 that will explore … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced the closing of its public offering of 2,106,000 units, with each consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.95. The warrants … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced completion of batch manufacturing of the DehydraTECH(TM)-processed cannabidiol (“CBD”) and placebo materials for its upcoming U.S. phase 1b hypertension clinical trial HYPER-H23-1. According to the update, Lexaria retained the services of a U.S. contract manufacturing organization to produce the materials compliant … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the results of the 2023 Annual Meeting. According to the update, the company held the meeting at 1:00 p.m. PT on May 9, 2023, whereby there were 3,372,024 shares of the company represented in person or by proxy, constituting 56.3% of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has completed dosing for 36 subjects in its human clinical oral nicotine study: NIC-H22-1. According to the announcement, the study is the result of the focus Lexaria has had for years on oral nicotine formulations as an alternative to vaping or smoking; the company noted … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms and the global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology – has announced that the company has received notification of four newly awarded or allowed patents (https://nnw.fm/SuJLp). The new patents will add … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) (https://nnw.fm/M4tkF). The report considers the potential approval and commercialization of products processed with the company’s patented DehydraTECH(TM) drug delivery platform technology that increases drug bioavailability, and ongoing research and development (“R&D”) activities, including … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zacks SCR”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. The company’s patented DehydraTECH(TM) drug delivery platform technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients. They recently completed its diabetes animal … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In Japan, the company secured a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria’s fifth awarded patent in … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since its inception, stayed committed to creating shareholder value and exploring different avenues for growth. This outlook has informed the company’s ambitious clinical studies, starting with the HYPER-H21-4 clinical study demonstrating a novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties”
